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Abstract
Comparative studies of colorectal cancer (CRC) according to the age of onset have
found differences between early-onset CRC (EOCRC) and late-onset CRC (LOCRC).
Using this as a starting point, we wished to determine whether intermediate-onset CRC
(IOCRC) might also be considered as an independent group within CRC. We performed
a retrospective comparative study of the clinicopathological and familial features, as
well as of the symptoms and their duration, of a total of 272 subjects diagnosed with
CRC classified into three groups according to the age-of-onset (98 EOCRC, 83 IOCRC
and 91 LOCRC). The results show that from a clinicopathological point of view, IOCRC
shared certain features with EOCRC (gender, prognosis), and with LOCRC (multiple pri-
mary CRCs), whereas it also had characteristics that were specific for IOCRC (mean
number of associated polyps). A gradual progression was observed from EOCRC to
LOCRC from a greater family aggregation to sporadic cases, in parallel with a change
of Lynch Syndrome cases to the sporadic microsatellite instability pathway, with the
IOCRC being a boundary group that is more related to EOCRC. With respect to symp-
toms, duration and correlation with stages, IOCRC appeared more similar to EOCRC.
Clinically, IOCRC behaves as a transitional group between EOCRC and LOCRC, with
features in common with both groups, but also with IOCRC-specific features. Excluding
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cases with familial cancer history, the awareness for EOCRC diagnosis should be
extended to IOCRC.
Introduction
Colorectal cancer (CRC) represents the third most common malignancy in developed coun-
tries [1,2]. Its pathogenesis is tightly related to the loss of genomic stability involving one of at
least three major molecular pathways: chromosomal instability (CIN), microsatellite instability
(MSI), and CpG island methylator phenotype (CIMP). The CIN pathway (also called the “sup-
pressor” pathway) accounts for the majority of spontaneous CRCs (85%) [3], and the MSI
pathway (also called the “mutator” pathway) accounts for about 15% of CRCs; these latter
cases are mainly related to Lynch syndrome (LS) and epigenetic silencing of the MLH1 gene
[4,5]. On the other hand, the CIMP pathway, by which methylation in the CpG islands causes
the silencing of genes, involved in almost 40% of CRCs [6,7].
Since the risk of developing CRC increases as individuals get older, early-onset CRC
(EOCRC) represents a rare entity commonly related to hereditary forms of the disease (2–8%
of all CRCs) [8]. It has been observed that MSI does not explain the majority of EOCRC cases,
and some authors have suggested that EOCRC should not be considered to be intimately asso-
ciated with hereditary forms of CRC [8–11]. From a clinical point of view, sporadic early-
onset tumors are more aggressive and confer poorer survival than the late-onset ones. They
are more frequently associated with invasive phenotypes, early metastasis, and familial cluster-
ing [8,9,12]. From a molecular point of view, EOCRCs show substantial dissimilarities regard-
ing the CIN pattern in comparison with LOCRC [13] and seem to be more frequently to
LINE-1 hypomethylation [14]. Consequently, it has been proposed that the molecular basis of
CRC might be different for different ages of onset [13].
Taking this as a starting point, the aim of the present study was to investigate whether inter-
mediate-onset CRC (IOCRC) (51–69 years old at the time of diagnosis) might also be consid-
ered as a different group within CRC according to the clinicopathological features of these
tumors or if, on the contrary, it should be interpreted as a transitional group between EOCRC
and LOCRC in which the clinicopathological features progressively vary from those typical in
EOCRC to those typical in LOCRC.
Materials and methods
Patients, samples and data collection
We compared three groups of patients diagnosed with CRC differing in the age at onset.
We collected 98 individuals diagnosed at an age of 50 years or younger (Early-onset CRC:
EOCRC), 83 individuals diagnosed at an age of 51–69 years (Intermediate-onset CRC:
IOCRC), and 91 individuals diagnosed at an age of 70 years or older (Late-onset CRC:
LOCRC). All patients were selected during the same period at the Hospital Universitario 12 de
Octubre in Madrid and provided written consent. In case of death of the index case, a first-
degree relative provided the consent. The study was approved by the Ethics Committee of the
“12 de Octubre” University Hospital (Madrid).
Family history of cancer (including at least three generations) and clinicopathological infor-
mation was obtained for each patient with a follow-up of at least 5 years from surgery. Personal
and clinicopathological information included age of onset, gender, location of the CRC, grade
of tumor differentiation, mucin production, the presence of “signet ring” cells, stage at
Intermediate-onset colorectal cancer
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diagnosis, the existence and type of polyps during follow-up and the presence of synchronous
or metachronous CRCs (SCRC or MCRC) were collected.
Symptoms and their duration at the time of diagnosis
All patients reported their symptoms and the duration of these symptoms at their first visit.
For incidental findings resulting in a diagnosis of CRC (e.g. anemia, screening strategies. . .),
the duration of the symptoms was considered as zero. Symptoms were defined as intestinal
bleeding (hematochezia, melena), changes in bowel habit (constipation and/or diarrhea),
constitutional syndrome (weight loss, anorexia and/or asthenia), anorectal symptoms (pain,
tenesmus), abdominal-related (pain, mass), unspecific symptoms (fatigue, bloating, nausea,
anemia-related symptoms), emergency diagnosis (bowel obstruction, acute abdominal pain)
and incidental diagnosis, as mentioned before. Finally, bleeding was defined as self-limited
(when colon bleeding was subsequent to therapeutic interventions), as associated with other
symptoms, or as isolated.
Molecular characterization of the tumors
A pathologist performed microscopic inspection of the tumor tissue of paraffin-embedded
samples from the index cases, and samples with more than 70% of tumor cells in the neoplastic
material were considered adequate for further analysis. The protocol for DNA isolation was as
previously reported [13].
We used the Bethesda panel to assess the MSI status and considered two or more altered
markers as a positive result [15]. We also considered tumors showing by immunohistochemistry
lack of expression of at least one mismatch repair (MMR) protein as MSI tumors. All MSI cases
were analyzed for the BRAF V600E mutation and hypermethylation of the MLH1 gene pro-
moter in order to confirm their sporadic nature [9], and prescreened for germline mutations in
MLH1, MSH2 and MSH6 by denaturing gradient gel electrophoresis (DGGE), denaturing high-
performance liquid chromatography (dHPLC), or high-resolution melting (HRM) analysis.
Primers and denaturing/melting conditions were as previously reported, with slight modifica-
tions [16]. When an anomalous band or pattern was observed by DGGE, dHPLC or HRM, the
PCR product was sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) and analyzed with an ABI Prism 3130 Genetic Analyzer (Applied Biosystems).
We also tested KRAS mutational status for known activating mutations by using polymer-
ase chain reaction amplification of codons 12,13, and 61, as well as by targeted next-generation
sequencing of all coding regions.
Statistical analyses
Continuous variables were expressed as mean values plus/minus standard deviation (SD), and
categorical variables were expressed as number of cases and their percentage. For the assessment
of associations between the age of onset and discrete variables, Pearson’s Chi Square (χ2) test
was used. For comparisons of continuous variables in more than two groups, the Kruskal-Wallis
test (nonparametric distributions) was used. Comparison of continuous variables was done
using Student´s t-test. Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago,
IL, USA), and differences were considered statistically significant when the p-value was<0.05.
Results
Clinical-pathological and familial features
Comparative results between the three CRC-onset categories are shown in Table 1.
Intermediate-onset colorectal cancer
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We observed a majority of male members in the younger groups (64% and 66% in EOCRC
and IOCRC respectively; p = 0.017), whereas the male/female ratio was close to one in the
LOCRC group. Differences regarding the tumor location according to the age at onset were
near-significant, and it is noteworthy that left-sided CRCs were predominant in EOCRC. A
mucinous histology and “signet ring” cells were also more frequent in the EOCRC group, but
statistical significance was only reached in the latter case (p = 0.039; Table 1). Interestingly, the
appearance of polyps during follow-up was more frequent in IOCRC and LOCRC (76% and
75%, respectively) than in EOCRC (66%) and the average number of polyps was significantly
higher in the IOCRC group (p = 0.027), while polyps of the adenomatous type were less fre-
quent in this group. Multiple primary CRCs (both S- and MCRC) were more frequent in
IOCRC and LOCRC (30% and 24%, respectively, versus 8% in EOCRC). Regarding survival,
Table 1. Clinical, pathological and familial features of the patients included in this study.
EOCRC IOCRC LOCRC p-valuea
No. of patients 98 (100) 83 (100) 91 (100) -
Mean age at onset ± SD (years) 41.01 ± 5.57 59.40 ± 4.87 77.49 ± 5.53 -
Gender:
Male
Female
63 (64)
35 (36)
55 (66)
28 (34)
43 (47)
48 (53)
0.017
Location:
Right colon
Left colon
Rectum
22 (22)
44 (45)
32 (33)
29 (35)
25 (30)
29 (35)
34 (37)
24 (27)
33 (36)
NS (0.052)
Tumor differentiationb: Poor 11/75 (15) 7/60 (12) 5/78 (6) NS
Mucin production2
“Signet ring” cells2
19/75 (25)
5/75 (7)
7/60 (12)
0/60 (0)
18/78 (23)
1/78 (1)
NS
0.039
Astler-Coller Stage:
A
B
C
D
25 (26)
33 (34)
18 (18)
22 (22)
26 (31)
20 (24)
17 (21)
20 (24)
6 (7)
43 (47)
18 (20)
24 (26)
0.002
Polyps during follow-up
Average No. of polyps
65 (66)
5.68 [3.00]
63 (76)
8.16 [5.00]
68 (75)
5.09 [3.00]
NS
0.027c
Type:
Adenomatous
Hyperplastic
Mixed
28 (43)
7 (11)
30 (46)
20 (32)
3 (5)
40 (63)
43 (63)
4 (6)
21 (31)
0.002
Synchronous/Metachronous CRC 8 (8) 25 (30) 22 (24) 0.001
OS ± SD (months)
DFS ± SD (months)
75.77 ± 47.82
66.00 ± 50.38
75.01 ± 41.43
65.19 ± 46.95
39.81 ± 27.27
31.49 ± 29.85
<0.001d
<0.001c
Family history of cancer:
Amsterdam II families
Aggregation for LR neoplasms
Sporadic cases
18 (18)
38 (39)
42 (43)
5 (6)
31 (37)
47 (57)
1 (1)
19 (21)
71 (78)
<0.001
Data shown in parenthesis represent percentages. Data shown in brackets represent median values.
aStatistical comparison was performed using Pearson’s Chi-Square (χ2) test.
bPercentages shown are based on varying total numbers as some cases were excluded because only one biopsy was taken (stage D), or because tumors were severely
dysplastic with “in situ” carcinoma and it was not possible to study any other characteristic.
cStatistical comparison was performed using the Kruskal-Wallis test.
dStatistical comparison was performed using analysis of variance (ANOVA). CRC: Colorectal cancer. DFS: Disease-free survival. EOCRC: Early-onset colorectal cancer.
IOCRC: Intermediate-onset colorectal cancer. LOCRC: Late-onset colorectal cancer. LR: Lynch-related. No.: Number. NS: Not significant. OS: Overall survival. SD:
Standard deviation.
https://doi.org/10.1371/journal.pone.0216472.t001
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EOCRC and IOCRC showed similar profiles (Overall survival: 75.77 and 75.01 months,
respectively; Disease-Free survival: 66 and 65.19 months, respectively), while within the
LOCRC group it was clearly worse (Overall survival: 39.81 months; and Disease-Free survival:
31.49 months). Finally, as expected, Amsterdam II criteria most frequently fulfilled in the
EOCRC group (18% of cases), and another 39% of cases in this group showed an aggregation
for LS neoplasms. This familial component decreased progressively through IOCRC (43% for
both together) until reaching 22% in LOCRC.
Symptoms and their duration at diagnosis
Global description. Information regarding the type of symptoms and their duration
could be obtained from 231 and 220 patients, respectively (Table 2).
Considering all patients, intestinal bleeding was the most common symptom (37%), fol-
lowed by changes in bowel habit (24%) and abdominal symptoms (22%). About 25% of
patients were diagnosed incidentally, and 43% of these were detected due to screening strate-
gies (as a result of familial and/or individual cancer history). Only 7% of the patients presented
an emergency diagnosis and required emergency surgery.
We observed different clinical manifestations depending on the tumor location (S1 Table):
right-sided tumors were more frequently associated with abdominal features (p = 0.005) and
rectal tumors were more frequently associated with intestinal bleeding (p = 0.0001) and with
changes in bowel habit (p = 0.03). On the other hand, left-sided tumors were most frequently
related to bowel obstruction although statistical significance was not reached. As expected,
anorectal symptoms were exclusively observed in rectal tumors. Finally, we also observed
some clear issues regarding the correlation between type/duration of the symptoms and the
stage of the cancer at the time of diagnosis (S2 Table). Thus, later stages of the disease were
often associated with abdominal symptoms or constitutional syndrome (p = 0.005 and
Table 2. Global shymptoms and their duration at the time of diagnosis.
EOCRC IOCRC LOCRC p-valuea
No. of patients 98 (100) 83 (100) 91 (100) -
Intestinal bleeding:
Associated
Isolated
Self-limited
38 (44)
20 (52)
9 (24)
9 (24)
23 (35)
14 (61)
5 (22)
4 (17)
25 (31)
11 (44)
2 (8)
12 (48)
NS
Abdominal symptoms 24 (28) 19 (29) 8 (10) 0.005
Constitutional syndrome 21 (24) 15 (23) 16 (20) NS
Anorectal (excluding bleeding) 1 (1) 2 (3) 1 (1) NS
Unspecific symptoms 10 (12) 6 (9) 7 (9) NS
Incidental diagnosis:
Anemia
Screening
Others
16 (19)
5 (31)
7 (44)
4 (25)
16 (25)
3 (19)
11 (69)
2 (12)
26 (33)
16 (62)
7 (27)
3 (11)
0.017
Changes in bowel habit 22 (26) 19 (29) 14 (18) NS
Emergency diagnosis 6 (7) 3 (5) 8 (10) NS
Duration of symptoms (months) 5.59 ± 8.59 4.46 ± 6.38 2.16 ± 3.42 0.001b
Data shown in parenthesis represent percentages.
aStatistical comparison was performed using Pearson’s Chi Square test (χ2).
bStatistical comparison was performed using the Kruskal-Wallis test. EOCRC: Early-onset colorectal cancer. IOCRC: Intermediate-onset colorectal cancer. LOCRC:
Late-onset colorectal cancer. No.: Number. NS: Not significant.
https://doi.org/10.1371/journal.pone.0216472.t002
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p = 0.006, respectively) whereas incidental diagnosis was more common in early stages.
Accordingly, stage I of the disease showed the lowest duration of the clinical symptoms, and
the increase correlated with increasing locoregional stage (stages I-III). Duration for remote
Stage IV cases was slightly less than Stage II cases.
Comparative analysis of symptoms and duration depending on the age of onset. In our
series, the duration of the symptoms was significantly longer in EOCRC (p = 0.001; Table 2),
with intestinal bleeding being the most frequent symptom (44%; Table 2). Abdominal symp-
toms were common in both EOCRC and IOCRC (about 30% in both cases), but relatively
uncommon in LOCRC (10%; p = 0.005) (Table 2). The LOCRC group showed the shortest
average time of symptomatic disease. Incidental diagnosis was more frequent in this group,
mostly due to anemia in analytical findings (p = 0.017; Table 2).
We also investigated the relationship between stages at diagnosis and clinical symptoms
for each age group and observed that some features became different compared with those
observed in the overall analysis (Table 3; S2 Table).
Thus, abdominal symptoms were prevalent in stage IV when all patients were considered,
but not when each group was studied separately. The most differential group was IOCRC, with
changes in bowel habit and constitutional syndrome being relatively frequent in stages II and
IV, respectively (Table 3). Incidental diagnosis predominated in both EOCRC and IOCRC
mainly due to screening strategies for stage I of the disease. Lastly, the duration of symptoms
increased in EOCRC and IOCRC in parallel with the stage of the disease, except for stage IV
where duration decreased with respect to foregoing stages (Table 3).
Molecular analysis
In our series, a total of 27 tumors showed MSI (14 EOCRC cases, 4 IOCRC cases and 9 LOCRC
cases) (Table 4) with a complete correlation with the immunohistochemical results. There were
no differences between groups according to the MSI (14%, 6% and 10%, respectively).
Blood samples were taken from the MSI index cases to assess germline mutations in MLH1,
MSH2, MSH6 and PMS2. MSI tumors were also analyzed for the BRAF V600E mutation and
MLH1 promoter hypermethylation, in order to identify sporadic cases.
Of the 14 MSI-EOCRC cases, 10 showed a pathogenic germline mutation in the MMR
genes (4 in MLH1, 4 in MSH2 and 2 in MSH6). Of the remaining four cases, two showed
hypermethylation of the MLH1 gene promoter and two, V600E BRAF mutation. The other
two patients showed lack of expression of MMR proteins but none of the above molecular
alterations was detected; therefore, these cases could be defined as Lynch-like syndrome cases
(Table 4). Regarding IOCRC, MSI was present in 4 of the 67 tumors that could be analyzed.
Of these 4 tumors, MSI was due to MMR germline mutations in 3 cases (2 had a mutation in
MSH2, and 1 in MSH6). The other one was a sporadic tumor with hypermethylation of the
MLH1 gene promoter. Finally, 9 tumors from LOCRC showed MSI. In this group, MSI was
mostly due to BRAF mutations and/or hypermethylation of the MLH1 gene promoter (eight
cases). The other case carried a mutation in the MSH2 gene.
According to KRAS mutations, there were no significant differences between groups,
although there was some gradual increase (39%, 48% and 56%, regarding EOCRC, IOCRC
and LOCRC subsets, respectively).
Discussion
In the last decades, CRC has become a major concern worldwide given its high prevalence
[1,2]. Although the incidence of this malignancy increases with age, a disturbing trend is being
observed in the last years in which the prevalence of sporadic cases in young adults seems to be
Intermediate-onset colorectal cancer
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increasing [13]. As a consequence, several studies focused on improving the characterization
of this disease according to the age of onset [13,17]. At present, the clinical manifestations of
sporadic EOCRC are known to differ from those observed in LOCRC. Furthermore, molecular
differences are also present, and some alterations occurring with different frequencies in both
age groups have been reported [13,17]. However, some publications analyzing differences
between early and late-onset CRC defined a specific cut-off age (usually 50 y/o), to divide them
into both categories [18], while others compared both without taking into account intermedi-
ate ages in order to reach more accuracy in the comparisons [9,11]. In the present study, we
aimed to determine what happens with patients with an intermediate age-of-onset of the dis-
ease, who do not belong to either EOCRC or LOCRC, and whether they could be considered a
boundary group or a different group by itself, within CRC.
Firstly, we compared clinicopathological and familial features of a cohort of 272 patients
differing in the age of onset (98 EOCRC, 83 IOCRC and 91 LOCRC). In our series, IOCRC
bore more resemblance to EOCRC in terms of sex ratio, stage and survival, whereas it bore
more resemblance to LOCRC in terms of colon location, development of polyps during fol-
low-up, and a trend to developing S- and MCRC. Interestingly, IOCRC behaved as a different
entity in histological terms, with mucin and signet ring cells being rare in this group (Table 1).
Although some authors have related mucin production with a poor prognosis [19–21], in our
series the mucinous component did not seem to be related to the prognosis of the disease; fea-
tures such as overall survival and disease-free survival were very similar to those observed in
EOCRC. The average number of polyps during follow-up was significantly higher in IOCRC
in comparison with EOCRC and LOCRC. Finally, regarding family history of cancer, cases
fulfilling the Amsterdam II criteria as well as families with aggregation for Lynch-related neo-
plasms were more common in EOCRC; the familial component decreased, and therefore the
number of sporadic cases increased, in a progressive manner to IOCRC and hence to LOCRC
(Table 1).
Regarding the type and duration of symptoms until diagnosis, LOCRC was the group
with the lowest number of symptoms at the time of diagnosis (p = 0.018). In our series,
IOCRC behaved as a transitional group between EOCRC and LOCRC. Accordingly, the
symptoms and their duration in patients diagnosed at intermediate ages were not specific,
but a gradation was observed from those most frequent in EOCRC to those most frequent
in LOCRC (Table 2). Thus, abdominal symptoms and changes in bowel habit became less
Table 4. Comparison and description of the molecular features according to the age of onset.
Total EOCRC IOCRC LOCRC
No. of patients 272 98 83 91
MSIa(%) 27/256 (11) 14/98 (14) 4/67 (6) 9/91 (10)
MMR genes affected:
MLH1
MSH2
MSH6
14
9
11
4
4
2
0
2
1
0
1
0
BRAF V600E mutation and/or MLH1 promoter
hypermethylation
11 2 1 8
KRAS mutationsa 116/256
(45)
38/98 (39) 32/67 (48) 51/91
(56)
a Percentages shown are based on varying total numbers as some cases were excluded because it was not possible to
study all characteristics of all patients. EOCRC: Early-onset colorectal cancer. IOCRC: Intermediate-onset colorectal
cancer. LOCRC: Late-onset colorectal cancer. MMR: Mismatch repair. MSI: Microsatellite instability. No.: Number.
https://doi.org/10.1371/journal.pone.0216472.t004
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frequent as the age at diagnosis increased, although statistical significance was only reached
in the first case (p = 0.005, Table 2). Incidental diagnosis was more frequent in LOCRC,
although the causes responsible for these findings were different in each age group. While
anemia was the main cause in elderly patients (possibly indicating a special awareness of
looking for CRC underlying this situation), in the younger groups the screening programs
became more important, especially in IOCRC. This fact was not surprising, considering that
the recommendations for CRC screening in our environment include periodic examinations
for all individuals without risk factors after the fifth decade of life, or at lower ages for indi-
viduals with a family history or other predisposing factors [22].
Apart from the age at diagnosis, we also compared the clinical manifestations depending on
tumor location and stage of the disease (S1 and S2 Tables). Abdominal and unspecific symp-
toms and incidental diagnoses were more frequent in right-sided tumors. By contrast, intesti-
nal bleeding and changes in bowel habit were most frequently observed in rectal tumors,
whereas in left-sided tumors bowel obstruction was predominant. Regarding the correlation
with tumor stages, we observed that advanced neoplasms usually showed a higher number of
symptoms and a higher frequency of appearance of all symptoms studied, except for changes
in bowel habit (p = 0.008). As expected, incidental diagnoses were more frequent in early
stages as a result of the widespread implementation of population screening programs
(p<0.001). To further asses the relationship between symptoms and tumor stages, we included
the age at diagnosis as a variable in order to detect possible differences between the groups
(Table 3). The trend of the results was along the same line as the one obtained without making
a differentiation according to age. However, it is important to point out that IOCRC was the
group in which the clinical manifestations differed most depending on the stage of the disease
at the moment of diagnosis. Our results confirm one of the main findings of the study of Chen
et al. [18] on age-of-onset and symptoms and their duration to diagnosis, even though they
analyzed EOCRC, as we did, but compared it with the rest of the population (older than 50) as
a whole. EOCRC cases experienced significantly longer symptom duration, as we found, show-
ing in our case the same results for IOCRC cases. However, in contrast to their finding that
EOCRC cases with stage III or IV disease had shorter symptom and work-up periods than
those with stage I or II disease, we found a correlative progression between symptoms duration
and advancing locoregional stages (I to III), but, in agreement with Chen et al. [18], it was
shorter only in stage IV tumors. Whereas in our opinion our findings show a more likely influ-
ence of the delay of diagnosis within locoregional stages, and of biological tumor factors in
relation with IV-stages, our data do underscore the necessity of a greater awareness of not only
EOCRC, but also of IOCRC.
Lastly, we evaluated the tumors from a MSI point of view and observed that IOCRC showed
the lowest rate of MSI, mainly due to germline mutations in the MMR genes, as well as a low
rate of BRAF mutations (Table 4). These findings seem to confirm our premise that the
IOCRC group may be a transitional group between EOCRC and LOCRC, because although
there was a decrease in cases with a family history of CRC from EOCRC to the group with
more sporadic tumors (LOCRC), the rate of LS cases decreased at the same time, and the num-
ber of MSI cases within LOCRC is mainly due to sporadic cases. According to KRAS muta-
tions, there was some gradual increase (39%, 48% and 56%, regarding EOCRC, IOCRC and
LOCRC subsets, respectively), being slightly like other publications [23].
From a clinical point of view, IOCRC appears to behave as a transitional group between
EOCRC and LOCRC, with common features with both groups, but also with group-specific
features. The variation of the familial component throughout the three categories and its dif-
ferential MSI component (Lynch syndrome component and sporadic cases) is interesting. In
order to find possible differential molecular bases for CRC according to the age-of-onset,
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future analyses should be carried out maintaining an upper limit of 50 y/o for EOCRC, and
comparing this group with both the IOCRC and LOCRC categories, or by using exclusively an
LOCRC group, but defined with a much higher age of onset than 50 y/o (e.g. 70 y/o), unless
large demographic studies could define a possible age-of-onset cut-off between only two main
different age-of-onset CRC populations. Finally, concerning symptoms and their duration
until diagnosis, and excluding cases with familial cancer history, the awareness for EOCRC
diagnosis should be extended to IOCRC.
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